Transition to a virtual multidisciplinary tumor board during the <scp>COVID</scp>‐19 pandemic: University of Pittsburgh experience
Harish Dharmarajan(University of Pittsburgh Medical Center), Mark Kubik(University of Pittsburgh), Katie Traylor(University of Pittsburgh Medical Center), Barton F. Branstetter(University of Pittsburgh Medical Center), Heath D. Skinner(University of Pittsburgh), Mario G. Solari(University of Pittsburgh Medical Center), Dan P. Zandberg(University of Pittsburgh Medical Center), Umamaheswar Duvvuri(City University of New York), Raja R. Seethala(University of Pittsburgh), Shaum Sridharan(University of Pittsburgh), James Ohr(University of Pittsburgh), Simion I. Chiosea(University of Pittsburgh), Marci L. Nilsen(University of Pittsburgh), Marion A. Hughes(University of Pittsburgh Medical Center), Robert L. Ferris(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Jonas T. Johnson(University of Pittsburgh), David A. Clump(West Virginia University), Jennifer L. Anderson(University of Pittsburgh Medical Center)
Cited by 88
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688